Neovacs S.A. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was EUR 0.538289 million compared to EUR 0.012555 million a year ago. Net loss was EUR 8.74 million compared to EUR 3.55 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0208 EUR | +57.58% | +63.78% | -98.96% |
Jun. 17 | Neovacs: collaboration agreement with CNRS | CF |
Jun. 10 | Neovacs: presents results from vaccine candidates | CF |
1st Jan change | Capi. | |
---|---|---|
-98.96% | 89.92K | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- ALNEV Stock
- News NEOVACS
- Neovacs S.A. Reports Earnings Results for the Full Year Ended December 31, 2023